Hysteroscopic Findings in Women Using Progesterone Only Pills (Minipills)

Sponsor
Samuel Gendy (Other)
Overall Status
Recruiting
CT.gov ID
NCT05024604
Collaborator
(none)
140
1
15.1
9.3

Study Details

Study Description

Brief Summary

Hysteroscopic findings in women using progesterone only pills (minipills) :A Prospective cohort study.

Condition or Disease Intervention/Treatment Phase
  • Drug: Progesterone Only Product in Oral Dose Form
  • Other: office hysterscopy

Detailed Description

Hysteroscopic findings in women using progesterone only pills (minipills) :A Prospective cohort study. versus women not using any hormonal therapy ,Office hysteroscopy would be conducted outside of the formal operating theater setting in an appropriately sized, equipped, and staffed treatment room with adjoining, private changing facilities and toilet. As the patient is aware of everything that is going on, it is advisable to organize a relaxed setting, using a protected space with a comfortable seat, Uterine distension:

When performing diagnostic hysteroscopic procedures, it is best if a non-viscous, physiologic solution is used i.e. Saline or Lactated Ringers as opposed to CO2 gas. CO2 is commonly used for diagnostic hysteroscopy but is difficult to use in the presence of blood or mucous. Adequate distention pressures (50-70 mmHG) can be achieved in the office by the use of gravity or a pressure bags. Most office based procedures are of short duration and no more than 2 liters of solution should be utilized. In this situation, it is not necessary to monitor fluid inflow, outflow and deficits in the office setting. The standard access approach to the cervix involves placing a speculum within the vagina (preferably side opening), placing single tenaculum on the anterior lip of the cervix, injecting the cervix with local anaesthesia (if necessary), and placing the rigid continuous flow hysteroscope within the cervical canal. In most patients, including nulliparous and post menopausal patients, it is not necessary to dilate the cervix prior to insertion. Once the hysteroscope is within the cervical canal, the speculum should be removed, the fluid flow is begun and the hysteroscope is advanced through the cervical canal and into the uterine cavity under direct visualization.

The endometrium will be inspected by outpatient hysteroscopy The following observations made at hysteroscopy, and reviewed in detail from the video record of the examination Glandular and stromal changes The color, thickness, texture and regularity of the endometrial stroma would be assessed during hysteroscopy Superficial vascular density Endometrial vascular density would be assessed at hysteroscopy by direct inspection of the blood vessels, and graded according to the abundance of superficial vessels observed. Superficial vascular density would be reassessed after uterine collapse and Re distention.

Vascular morphology The shape and configuration of superficial and deep endometrial vessels would be assessed at hysteroscopy. The presence of regular and irregular (neo vascular and mosaic) vascular patterns in superficial and deep vessels would be recorded and graded. The presence of petechiae and ecchymosis would be recorded.

All the above values were regraded after collapse and re distention of the uterus, provided that a clear view of the endometrium could be obtained.

Vascular distribution The distribution of superficial and deep vasculature in the endometrium would be inspected and graded as even' or 'patchy'.

Endometrial biopsies biopsies would be taken at each hysteroscopy. A small amount of endometrial tissue was obtained under direct vision using the biopsy curette (novak curette). also a detailed comment by the examiner would be given regarding the uterine ostium of the fallopian tube & any changes in the cervical canal and the cervical secretions any abnormal findings or pathology would be mentioned also .

Study Design

Study Type:
Observational
Anticipated Enrollment :
140 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Hysteroscopic Findings in Women Using Progesterone Only Pills (Minipills) Prospective Cohort Study .
Anticipated Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Dec 5, 2022

Arms and Interventions

Arm Intervention/Treatment
study group

women receiving mini pills as a method of contraception with symptoms not diagnosed with us

Drug: Progesterone Only Product in Oral Dose Form
mini pills as a contraceptive method

Other: office hysterscopy
office hysteroscoy

Control group

women attending to office hysteroscopy unit and not taking hormonal therapy

Other: office hysterscopy
office hysteroscoy

Outcome Measures

Primary Outcome Measures

  1. primary outcome [an average of 1 year]

    Hysteroscopic findings in women using POPs versus those not using hormones.( cervical mucosa , endometrium )

Secondary Outcome Measures

  1. subsidiary [an average of 1 year]

    documentation of the local effects of POPs as a method of contraception

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
  • study group:

  • women using POP.

  • Age: reproductive age.

  • Symptoms: abnormal uterine bleeding without an organic cause.

2-Authorization to participate in the study .

  • Control group

1- women attending to office hysteroscopy clinic

  • Age: reproductive Age

  • Contraception use : none.

  • Hormonal use: none.

  • Symptoms: abnormal uterine bleeding without an organic cause. All women in both groups would be subjected to Trans Vaginal U.S before doing hysteroscopy .

  1. Exclusion criteria:
  • study group

  • Coagulopathies

  • Any contraindications to POPs as :

  • past or current breast cancer, cirrhosis, and use of anticonvulsants

  • suspected pregnancy

  • current stroke or IHD

  • severe hypertension

•Any contraindications to hysteroscopy as :

  • Pelvic infection

  • Pregnancy

  • Cervical cancer

  • Heavy uterine bleeding.

  • Control group --Women using any type of hormones including COCs .

Contacts and Locations

Locations

Site City State Country Postal Code
1 Women health hospital , Assuit university Assiut Assuit Egypt 71515

Sponsors and Collaborators

  • Samuel Gendy

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Samuel Gendy, Resident of Obstetrics & Gynecology, Assiut University
ClinicalTrials.gov Identifier:
NCT05024604
Other Study ID Numbers:
  • 117101333
First Posted:
Aug 27, 2021
Last Update Posted:
Aug 27, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 27, 2021